Biora Therapeutics Inc
NASDAQ:BIOR
Biora Therapeutics Inc
Research & Development
Biora Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
Research & Development
-$29.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CVS Health Corp
NYSE:CVS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cigna Corp
NYSE:CI
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Research & Development
-$364.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Biora Therapeutics Inc
Glance View
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
See Also
What is Biora Therapeutics Inc's Research & Development?
Research & Development
-29.8m
USD
Based on the financial report for Dec 31, 2023, Biora Therapeutics Inc's Research & Development amounts to -29.8m USD.
What is Biora Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
9%
Over the last year, the Research & Development growth was -24%. The average annual Research & Development growth rates for Biora Therapeutics Inc have been 14% over the past three years , 9% over the past five years .
